During the past decade, Onze Lieve Vrouw Ziekenhuis conducted 181 clinical trials. In the 10-year time frame, 181 clinical trials started and 48 clinical trials were completed, i.e. on average, 26.5% percent of trials that started reached the finish line to date. In the past 5 years, 83 clinical trials started and 29 clinical trials were completed. i.e. 34.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Onze Lieve Vrouw Ziekenhuis" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 15 trials, followed by "Onze Lieve Vrouw Hospital" with 13 trials sponsored, "Universitaire Ziekenhuizen KU Leuven" with 13 trials sponsored, "ID3 Medical" with 11 trials sponsored and "Abbott Medical Devices" with 11 trials sponsored. Other sponsors include 194 different institutions and companies that sponsored additional 110 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onze Lieve Vrouw Ziekenhuis" #1 collaborator was "Onze Lieve Vrouw Hospital" with 6 trials as a collaborator, "University Hospital, Antwerp" with 6 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 4 trials as a collaborator, "Universitair Ziekenhuis Brussel" with 4 trials as a collaborator and "Agentschap voor Innovatie door Wetenschap en Technologie" with 3 trials as a collaborator. Other collaborators include 248 different institutions and companies that were collaborators in the rest 226 trials.

According to Clinical.Site data, the most researched conditions in "Onze Lieve Vrouw Ziekenhuis" are "Peripheral Arterial Disease" (25 trials), "Coronary Artery Disease" (22 trials), "Atrial Fibrillation" (19 trials), "Heart Failure" (12 trials) and "Stroke" (8 trials). Many other conditions were trialed in "Onze Lieve Vrouw Ziekenhuis" in a lesser frequency.

Most popular intervention types in "Onze Lieve Vrouw Ziekenhuis" are "Device" (111 trials), "Drug" (101 trials), "Other" (30 trials), "Procedure" (19 trials) and "Biological" (13 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (17 trials), "Paclitaxel" (4 trials), "Atezolizumab" (3 trials), "Carboplatin" (3 trials) and "Oxaliplatin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Onze Lieve Vrouw Ziekenhuis" are 231 trials for "All" genders, 15 trials for "Female" genders and 15 trials for "Male" genders.

Currently, there are 89 active trials in "Onze Lieve Vrouw Ziekenhuis". 2 are not yet recruiting, 46 are recruiting, 39 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 137 completed trials in Onze Lieve Vrouw Ziekenhuis, undefined suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Onze Lieve Vrouw Ziekenhuis, 5 "Phase 1" clinical trials were conducted, 34 "Phase 2" clinical trials and 66 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 29 trials, and there were also 84 trials that are defined as “Not Applicable".

Onze Lieve Vrouw Ziekenhuis has several departments that took part in Clinical trials: "Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium" - 2 trials